Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench.
Coles
Alasdair
A
Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 2QQ, UK. ajc1020@medschl.cam.ac.uk
Deans
Jackie
J
Compston
Alastair
A
D000328:Adult; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015704:CD4 Antigens / Q000187:drug effects; D016827:CD8 Antigens / Q000187:drug effects; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D015704:CD4 Antigens; D016827:CD8 Antigens; D000074323:Alemtuzumab